×
About 2,699 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  1,065 results

INCREASED GROUP 2 INNATE LYMPHOID CELLS IN PERIPHERAL BLOOD OF ADULTS WITH MASTOCYTOSIS.
https://doi.org/10.1016/j.jaci.2020.09.037
The Journal of Allergy and Clinical Immunology; van der Ploeg EK, Hermans MAW et. al.

Oct 22nd, 2020 - Systemic mastocytosis is a hematological disease in which aberrant mast cells accumulate due to gain-of-function mutations in the KIT receptor. Group 2 innate lymphoid cells (ILC2s) are effector cells of type 2 immune responses that also express K...

Graft-versus-Mastocytosis Effect After Donor Lymphocyte Infusion: Proof of Principle.
https://doi.org/10.1111/ejh.13528
European Journal of Haematology; Hägglund H, Selim Yavuz A et. al.

Oct 3rd, 2020 - Advanced systemic mastocytosis is a relatively rare entity where allogeneic stem cell transplantation can lead to cure of the disease in selected patients. Delayed incomplete responses with graft versus mastocytosis effect were published in a few ...

Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia.
https://doi.org/10.1097/ACI.0000000000000678
Current Opinion in Allergy and Clinical Immunology; O'Connell MP, Lyons JJ

Aug 9th, 2020 - To discuss the association between the common dominantly inherited genetic trait hereditary alpha-tryptasemia (HαT) and hymenoptera venom-induced anaphylaxis (HVA). Elevated BST has been correlated with more severe systemic anaphylaxis in humans i...

Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential ...
https://doi.org/10.1002/cyto.b.21938
Cytometry. Part B, Clinical Cytometry REFERENCES; Panda D, Chatterjee G et. al.

Jul 31st, 2020 - Myeloid neoplasm with blasts showing mast cell (MC)-differentiation and MC-component less than 10% of all nucleated cells but not fulfilling the criteria for systemic mastocytosis with associated hematological neoplasm (SM-AHN) or myelomastocytic ...

Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding ger...
https://doi.org/10.1016/j.jaci.2020.06.035
The Journal of Allergy and Clinical Immunology; Lyons JJ, Chovanec J et. al.

Jul 27th, 2020 - An elevated basal serum tryptase level is associated with severe systemic anaphylaxis, most notably caused by Hymenoptera envenomation. Although clonal mast cell disease is the culprit in some individuals, it does not fully explain this clinical a...

see more →

Guidelines  2 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JNCCN; Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

see more →

Drugs  251 results see all →

Clinicaltrials.gov  1,345 results

INCREASED GROUP 2 INNATE LYMPHOID CELLS IN PERIPHERAL BLOOD OF ADULTS WITH MASTOCYTOSIS.
https://doi.org/10.1016/j.jaci.2020.09.037
The Journal of Allergy and Clinical Immunology; van der Ploeg EK, Hermans MAW et. al.

Oct 22nd, 2020 - Systemic mastocytosis is a hematological disease in which aberrant mast cells accumulate due to gain-of-function mutations in the KIT receptor. Group 2 innate lymphoid cells (ILC2s) are effector cells of type 2 immune responses that also express K...

Ranitidine - ranitidine tablet-Bryant Ranch Prepack
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10787d51-1dd5-47b4-8bd3-02f50ea26a63

Oct 15th, 2020 - Ranitidine Tablets, USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more th...

Graft-versus-Mastocytosis Effect After Donor Lymphocyte Infusion: Proof of Principle.
https://doi.org/10.1111/ejh.13528
European Journal of Haematology; Hägglund H, Selim Yavuz A et. al.

Oct 3rd, 2020 - Advanced systemic mastocytosis is a relatively rare entity where allogeneic stem cell transplantation can lead to cure of the disease in selected patients. Delayed incomplete responses with graft versus mastocytosis effect were published in a few ...

Ranitidine - ranitidine tablet, film coated-Preferred Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=390ca7d1-eb49-490d-82ed-34f656c7b2b2

Sep 3rd, 2020 - Ranitidine tablets USP are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more t...

Ranitidine - ranitidine tablet-Preferred Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e466ae5-a284-49be-b7a5-0f135e3ab9f4

Sep 3rd, 2020 - Ranitidine Tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than...

see more →

News  31 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

Avapritinib yields high response rate in patients with systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/153966/myelodysplastic-syndrome/avapritinib-yields-high-response-rate
Andrew D. Bowser

Dec 10th, 2017 - ATLANTA – An oral investigational drug with specific activity against a mutation frequently found in advanced systemic mastocytosis (ASM) produced clinical responses in the majority treated patients, according to preliminary data presented at the.

see more →

Patient Education  5 results see all →